107 related articles for article (PubMed ID: 29536433)
21. Baseline characteristics and effects of growth hormone therapy over two years in younger and elderly adults with adult onset GH deficiency.
Franco C; Johannsson G; Bengtsson BA; Svensson J
J Clin Endocrinol Metab; 2006 Nov; 91(11):4408-14. PubMed ID: 16940452
[TBL] [Abstract][Full Text] [Related]
22. A therapeutic trial of growth hormone in hypopituitary adults and its influence upon continued prescription by general practitioners.
Davies JS; Obuobie K; Smith J; Rees DA; Furlong A; Davies N; Evans LM; Scanlon MF
Clin Endocrinol (Oxf); 2000 Mar; 52(3):295-303. PubMed ID: 10718827
[TBL] [Abstract][Full Text] [Related]
23. Influences on quality of life in GH deficient adults and their effect on response to treatment.
Murray RD; Skillicorn CJ; Howell SJ; Lissett CA; Rahim A; Smethurst LE; Shalet SM
Clin Endocrinol (Oxf); 1999 Nov; 51(5):565-73. PubMed ID: 10594517
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular Risk in Growth Hormone Deficiency: Beneficial Effects of Growth Hormone Replacement Therapy.
Lanes R
Endocrinol Metab Clin North Am; 2016 Jun; 45(2):405-18. PubMed ID: 27241971
[TBL] [Abstract][Full Text] [Related]
25. Trajectory of body shape across the lifespan and cancer risk.
Song M; Willett WC; Hu FB; Spiegelman D; Must A; Wu K; Chan AT; Giovannucci EL
Int J Cancer; 2016 May; 138(10):2383-95. PubMed ID: 26704725
[TBL] [Abstract][Full Text] [Related]
26. Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (HypoCCS) according to tertiles of growth hormone peak concentration following stimulation testing at study entry.
Losa M; Beck-Peccoz P; Aimaretti G; Di Somma C; Ambrosio MR; Ferone D; Giampietro A; Corsello SM; Poggi M; Scaroni C; Jia N; Mossetto G; Cannavò S; Rochira V
Clin Endocrinol (Oxf); 2015 Oct; 83(4):527-35. PubMed ID: 26119712
[TBL] [Abstract][Full Text] [Related]
27. The robustness of diagnostic tests for GH deficiency in adults.
Andersen M
Growth Horm IGF Res; 2015 Jun; 25(3):108-14. PubMed ID: 25900364
[TBL] [Abstract][Full Text] [Related]
28. Growth hormone replacement in adults - current standards and new perspectives.
Höybye C; Christiansen JS
Best Pract Res Clin Endocrinol Metab; 2015 Jan; 29(1):115-23. PubMed ID: 25617177
[TBL] [Abstract][Full Text] [Related]
29. Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations.
Bidlingmaier M; Friedrich N; Emeny RT; Spranger J; Wolthers OD; Roswall J; Körner A; Obermayer-Pietsch B; Hübener C; Dahlgren J; Frystyk J; Pfeiffer AF; Doering A; Bielohuby M; Wallaschofski H; Arafat AM
J Clin Endocrinol Metab; 2014 May; 99(5):1712-21. PubMed ID: 24606072
[TBL] [Abstract][Full Text] [Related]
30. Hormones and cardiovascular disease in older men.
Yeap BB; Flicker L
J Am Med Dir Assoc; 2014 May; 15(5):326-33. PubMed ID: 24529874
[TBL] [Abstract][Full Text] [Related]
31. Abnormal metabolic phenotype in middle-aged GH-deficient adults despite long-term recombinant human GH replacement.
Claessen KM; Appelman-Dijkstra NM; Pereira AM; Joustra SD; de Mutsert R; Gast KB; den Heijer M; Smit JW; Dekkers OM; Biermasz NR
Eur J Endocrinol; 2014 Feb; 170(2):263-72. PubMed ID: 24217935
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH--an update.
Gazzaruso C; Gola M; Karamouzis I; Giubbini R; Giustina A
J Clin Endocrinol Metab; 2014 Jan; 99(1):18-29. PubMed ID: 24217903
[TBL] [Abstract][Full Text] [Related]
33. Serum levels of bioactive IGF1 and physiological markers of ageing in healthy adults.
Vestergaard PF; Hansen M; Frystyk J; Espelund U; Christiansen JS; Jørgensen JO; Fisker S
Eur J Endocrinol; 2014 Feb; 170(2):229-36. PubMed ID: 24179101
[TBL] [Abstract][Full Text] [Related]
34. Update in mortality in GH-treated patients.
Erfurth EM
J Clin Endocrinol Metab; 2013 Nov; 98(11):4219-26. PubMed ID: 24030944
[TBL] [Abstract][Full Text] [Related]
35. Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review.
Appelman-Dijkstra NM; Claessen KM; Roelfsema F; Pereira AM; Biermasz NR
Eur J Endocrinol; 2013 Jul; 169(1):R1-14. PubMed ID: 23572082
[TBL] [Abstract][Full Text] [Related]
36. Fifteen years of GH replacement improves body composition and cardiovascular risk factors.
Elbornsson M; Götherström G; Bosæus I; Bengtsson BÅ; Johannsson G; Svensson J
Eur J Endocrinol; 2013 May; 168(5):745-53. PubMed ID: 23428613
[TBL] [Abstract][Full Text] [Related]
37. Serum IGF1, metabolic syndrome, and incident cardiovascular disease in older people: a population-based study.
van Bunderen CC; Oosterwerff MM; van Schoor NM; Deeg DJ; Lips P; Drent ML
Eur J Endocrinol; 2013 Mar; 168(3):393-401. PubMed ID: 23233113
[TBL] [Abstract][Full Text] [Related]
38. Aging, atherosclerosis, and IGF-1.
Higashi Y; Sukhanov S; Anwar A; Shai SY; Delafontaine P
J Gerontol A Biol Sci Med Sci; 2012 Jun; 67(6):626-39. PubMed ID: 22491965
[TBL] [Abstract][Full Text] [Related]
39. The pituitary gland and age-dependent regulation of body composition.
van Beek AP; Wolffenbuttel BH; Runge E; Trainer PJ; Jönsson PJ; Koltowska-Häggström M
J Clin Endocrinol Metab; 2010 Aug; 95(8):3664-74. PubMed ID: 20484487
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
